Chimeric respiratory syncytial virus (RSV) polypeptide antigens are provided. The disclosed polypeptides include a first amino acid sequence comprising an F2 domain uncleavably joined to an Fl domain of a Respiratory Syncytial Virus (RSV) Fusion (F) protein polypeptide and a second amino acid sequence comprising a portion of an RSV Attachment (G) protein polypeptide comprising an immunologically dominant epitope.. The disclosure also provides nucleic acids that encode, and pharmaceutical compositions that contain, the chimeric RSV polypeptides, as well as methods for their production and use.
